The ROCKET (Rivaroxaban Once‐daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial) trial also identified reduced serum albumin and platelet count,6 two parameters that were not available for patients in this study. The gene discussed is TNXA; the disease is stroke disorder.